RTP Mobile Logo

Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma

Submitted by web@researchtop... on Fri, 11/22/2013 - 17:16

Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma

Submitted by web@researchtop... on Fri, 11/22/2013 - 17:16

Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma

Submitted by web@researchtop... on Fri, 11/22/2013 - 17:15

Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma

Submitted by web@researchtop... on Fri, 11/22/2013 - 17:15

Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma

Submitted by web@researchtop... on Fri, 11/22/2013 - 17:14

Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma

Submitted by web@researchtop... on Fri, 11/22/2013 - 17:14

Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma

Submitted by web@researchtop... on Fri, 11/22/2013 - 17:01

SAMPLE FOR NHLTT VIDEOS (links on transcription)

Submitted by web@researchtop... on Tue, 11/19/2013 - 12:02

SAMPLE FOR NHLTT VIDEOS (links on transcription)

Submitted by web@researchtop... on Tue, 11/19/2013 - 11:33

Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma

Submitted by web@researchtop... on Tue, 11/19/2013 - 11:16

75 yo w/ MSS T3 (1/20 node pos) tumor

Submitted by Anonymous on Wed, 11/13/2013 - 17:34

75 yo w/ MSS T3 (1/20 node pos) tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?

Would you offer an Oncotype DX assay for an otherwise healthy 75-year-old patient with a Grade II, MSS T3 (1 out of 20 nodes positive) tumor?

If not, what adjuvant systemic therapy would you likely recommend for this patient?

60 yo w/ MSS T4N0 tumor

Submitted by Anonymous on Wed, 11/13/2013 - 17:27

60 yo w/ MSS T4N0 tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?

Would you offer an Oncotype DX assay for an otherwise healthy 60-year-old patient with a Grade II, MSS T4N0 (0 out of 20 nodes positive) tumor?

If not, what adjuvant systemic therapy would you likely recommend for this patient?

60 yo w/ MSS T3N0 tumor

Submitted by Anonymous on Wed, 11/13/2013 - 17:21

60 yo w/ MSS T3N0 tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?

Would you offer an Oncotype DX® assay for an otherwise healthy 60-year-old patient with a Grade II, microsatellite stable (MSS) T3N0 (0 out of 20 nodes positive) tumor?

If not, what adjuvant systemic therapy would you likely recommend for this patient?

75 yo w/ MSS T3 (1/20 node pos) tumor

Submitted by Anonymous on Wed, 11/13/2013 - 17:09

75 yo w/ MSS T3 (1/20 node pos) tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?

Would you offer an Oncotype DX assay for an otherwise healthy 75-year-old patient with a Grade II, MSS T3 (1 out of 20 nodes positive) tumor?

If not, what adjuvant systemic therapy would you likely recommend for this patient?

Consensus or Controversy, Issue 4: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Adjuvant Treatment of Colorectal Cancer

Submitted by web@researchtop... on Wed, 11/13/2013 - 15:51